NCT04949282 Spanish Series of Patients Treated With the Radionuclide Lutetium177
| NCT ID | NCT04949282 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sociedad Española de Medicina Nuclear e Imagen Molecular |
| Condition | Neuroendocrine Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2021-05-10 |
| Primary Completion | 2034-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2021-05-10 with a primary completion date of 2034-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Eligibility Criteria
Inclusion Criteria: * Written informed consent must be obtained prior to any data collection. * Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour * Aged ≥18 years. Exclusion Criteria: * None
Contact & Investigator
Mercedes Dr Mitjavila Casanovas, MD-PhD
PRINCIPAL INVESTIGATOR
Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM)
Frequently Asked Questions
Who can join the NCT04949282 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Neuroendocrine Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04949282 currently recruiting?
Yes, NCT04949282 is actively recruiting participants. Contact the research team at mercedes.mitjavila@salud.madrid.org for enrollment information.
Where is the NCT04949282 trial being conducted?
This trial is being conducted at Santiago de Compostela, Spain, Granada, Spain, Palma de Mallorca, Spain, L'Hospitalet de Llobregat, Spain and 11 additional locations.
Who is sponsoring the NCT04949282 clinical trial?
NCT04949282 is sponsored by Sociedad Española de Medicina Nuclear e Imagen Molecular. The principal investigator is Mercedes Dr Mitjavila Casanovas, MD-PhD at Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM). The trial plans to enroll 5,000 participants.